Among these antigen peptides, melanoma antigen recognized by T cells 1 (MART-1), melanoma-associated antigen C2 (MAGE C2), preferentially expressed antigen of melanoma (PRAME), solute carrier family 45 member 2 (SLC45A2), and glycoprotein (gp100) are highly expressed in uveal melanoma tumors and are currently being evaluated in TCR-based clinical trials for the treatment of mUM. The gene discussed is MAGEC2; the disease is melanoma.